Department of Medicine (Neurology), University of Manitoba, Winnipeg, Manitoba, Canada.
Exp Neurol. 2010 Nov;226(1):231-41. doi: 10.1016/j.expneurol.2010.09.003. Epub 2010 Sep 9.
Chronic CNS infection by several families of viruses can produce deficits in prefrontal cortex (PFC) and striatal function. Cannabinoid drugs have been long known for their anti-inflammatory properties and their ability to modulate adult neuro and gliogenesis. Therefore, we explored the effects of systemic administration of the cannabinoid agonist WIN55,212-2(WIN) on prefrontal cortex (PFC) and striatal cytogenesis in a viral model of CNS injury and inflammation based on Borna Disease (BD) virus encephalitis. Active BrdU(+) progenitor populations were significantly decreased 1 week after BrdU labeling in BD rats [p<0.001 compared to uninfected (NL) controls] while less than 5% of BrdU(+) cells colabeled for BDV protein. Systemic WIN (1mg/kg i.p. twice daily×7 days) increased the survival of BrdU(+) cells in striatum (p<0.001) and PFC of BD rats, with differential regulation of labeled oligodendroglia precursors vs microglia/macrophages. WIN increased the percentage of BrdU(+) oligodendrocyte precursor cells and decreased BrdU(+) ED-1-labeled phagocytic cells, without producing pro- or antiviral effects. BDV infection decreased the levels of the endocannabinoid anandamide (AEA) in striatum (p<0.05 compared to NL rats), whereas 2-AG levels were unchanged. Our findings indicate that: 1) viral infection is accompanied by alterations of AEA transmission in the striatum, but new cell protection by WIN appears independent of its effect on endocannabinoid levels; and 2) chronic WIN treatment alters the gliogenic cascades associated with CNS injury, promoting oligodendrocyte survival. Limiting reactive gliogenesis and macrophage activity in favor of oliogodendroglia development has significance for demyelinating diseases. Moreover, the ability of cannabinoids to promote the development of biologically supportive or symbiotic oligodendroglia may generalize to other microglia-driven neurodegenerative syndromes including NeuroAIDS and diseases of aging.
几种病毒家族引起的慢性中枢神经系统感染可导致前额叶皮层(PFC)和纹状体功能缺陷。大麻素类药物长期以来因其抗炎特性和调节成人神经和神经发生的能力而闻名。因此,我们探索了全身性给予大麻素激动剂 WIN55,212-2(WIN)对基于博尔纳病(BD)病毒脑炎的中枢神经系统损伤和炎症病毒模型中的前额叶皮层(PFC)和纹状体细胞发生的影响。与未感染(NL)对照相比,BD 大鼠在 BrdU 标记后 1 周时,活跃的 BrdU(+)祖细胞群体明显减少[ p<0.001],而少于 5%的 BrdU(+)细胞与 BDV 蛋白共标记。全身性 WIN(1mg/kg i.p. 每日两次×7 天)增加了 BD 大鼠纹状体( p<0.001)和 PFC 中 BrdU(+)细胞的存活率,对标记的少突胶质细胞前体与小胶质细胞/巨噬细胞进行了差异调节。WIN 增加了 BrdU(+)少突胶质细胞前体细胞的百分比,并减少了 BrdU(+)ED-1 标记的吞噬细胞,而没有产生促病毒或抗病毒作用。BDV 感染降低了纹状体中的内源性大麻素大麻酰胺(AEA)水平(与 NL 大鼠相比, p<0.05),而 2-AG 水平不变。我们的发现表明:1)病毒感染伴随着纹状体中 AEA 传递的改变,但是 WIN 的新细胞保护作用似乎与其对内源性大麻素水平的作用无关;2)慢性 WIN 治疗改变了与中枢神经系统损伤相关的神经发生级联反应,促进少突胶质细胞存活。限制反应性神经发生和巨噬细胞活性有利于少突胶质细胞发育,对脱髓鞘疾病具有重要意义。此外,大麻素促进具有生物支持或共生作用的少突胶质细胞发育的能力可能推广到其他包括神经艾滋病和衰老疾病在内的由小胶质细胞驱动的神经退行性综合征。